



Immuron to Repay Outstanding Convertible Note in Cash

Melbourne, Australia, 18 July, 2016: Immuron Limited (ASX:IMC), is pleased to announce that following the Company's recent Rights Issue raising of \$5.33M which received strong support from both existing shareholders and new investors, the Company will be able to execute its commitment to shareholders to repay all future obligations pertaining to the Sea Otter Convertible Note in cash, rather than via the issuance of new securities.

In February 2016, the Company received a Convertible Note facility of up to \$1.7M of interim funding from US-based Investment Fund Sea Otter whilst the Company finalised its capital raising campaign in Australia.

As at today, the Convertible Note liability is \$1,130,000 which is repayable in equal amounts over the next 15 months. Under the Agreement, whilst repaying the Convertible note in cash attracts a 2.5% repayment premium, the Company believes this to be the optimal option as the alternative is to repay the tranches via the issuance of new shares at a price equal to a 10% discount to the VWAP of the lowest 5 trading days in the prior months trading.

As the company now has the funding to repay the convertible note tranches in cash, this is advantageous for shareholders as it has a non-dilutive effect on their ownership percentage.

Immuron CEO Mr Thomas Liquard said;

"We have been fortunate to work with Sea Otter and are thankful to them that they were able to provide us with the interim funding facility we needed to provide us with near-term financial flexibility.

As per our Rights Issue commitment to our shareholders, we will now repay all future obligations for this Convertible Note in cash which will be advantageous to all shareholders."

-- END --

Company Contact:

Thomas Liquard
Chief Executive Officer
AUS Ph: +61 (0)3 9824 5254
thomasliquard@immuron.com

Immuron US Investor Relations:

Jon Cunningham
RedChip Companies, Inc.
US Ph: +1 (407) 644 4256, (ext. 107)
jon@redchip.com

About Immuron:

Immuron Ltd (ASX: IMC; OTCQB: IMROY) is a microbiome company focused on developing and commercializing oral immunotherapeutics for the treatment of a many gut mediated diseases. Immuron has a unique and safe technology platform that enables a shorter development therapeutic cycle. The Company currently markets and sells Travelan® for the prevention of Travelers' diarrhea, whilst its lead product candidate IMM-124E is in Phase 2b clinical trials for NASH and ASH. These products together with the Company's other preclinical immunotherapy pipeline products targeting immune-related diseases currently under development, will meet a large unmet need in the market.

For more information visit: www.immuron.com

Forward-Looking Statements:

Certain statements made in this release are forward-looking statements and are based on Immuron's current expectations, estimates and projections. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance" and similar expressions are intended to identify forward-looking statements. Although Immuron believes the forward-looking statements are based on reasonable assumptions, they are subject to certain risks and uncertainties, some of which are beyond Immuron's control, including those risks or uncertainties inherent in the process of both developing and commercialising technology. As a result, actual results could materially differ from those expressed or forecasted in the forward-looking statements. The forward-looking statements made in this release relate only to events as of the date on which the statements are made. Immuron will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this release except as required by law or by any appropriate regulatory authority.